Back to World
World
1 September 2026
Drug Farm Presents Positive Ophthalmologic and Systemic Findings from International Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at APVRS 2026
Drug Farm today announced positive ophthalmologic and systemic findings from its international Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, presented at the Asia-Pacific ...
About this report
This article contains independently written commentary and community perspective from Downunder Voices.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
